-
Repros Therapeutics Shares Rally Following Ladenburg Upgrade To Buy, Positive Data
Wednesday, November 16, 2016 - 11:43am | 299Read More...Shares of Repros Therapeutics Inc (NASDAQ: RPRX) climbed more than 8 percent in Wednesday’s pre-market hours after positive clinical data of Proellex led Ladenburg Thalmann to upgrade shares to Buy, with a $5.50 price target. Repros announced positive Phase 2b data for both its oral and...
-
Repros Therapeutics Surges 60% Following Encouraging Study Results
Wednesday, April 13, 2016 - 7:26am | 163Read More...Shares of Repros Therapeutics Inc (NASDAQ: RPRX), a nano-cap biopharmaceutical company that focuses on the treatment of hormonal and reproductive system disorders, is surging higher by 60 percent. Repros Therapeutics reported after Tuesday's close that patients receiving 6 and 12 mg doses...
